

- patients with stage I nonsmall cell lung carcinoma. *Cancer* **78**, 1892-1898.
- Galligioni, E., Quaia, M., Merlo, A., Carbone, A., Spada, A., Favaro, D., Santarosa, M., Sacco, C., Talamini, R. (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. *Cancer* **77**, 2560-2566.
- Gebrosky, N. P., Koukol, S., Nseyo, U. O., Carpenter, C., Lamm, D. L. (1997) Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon. *Urology* **50**, 863-867.
- Hao, D., Huan, S. D., Stewart, D. J., Segal, R. J., Yau, J. C. (2000) A pilot study of low dose hydroxyurea as a novel resistance modulator in metastatic renal cell cancer. *J. Chem.* **12**, 360-366.
- Heinzer, H., Mir, T., Huland, E., Huland, H. (1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. *J. Clin. Oncol.* **17**, 3612-3620.
- Henriksson, R., Nilsson, S., Colleen, S., Wersall, M., Helsing, M., Zimmerman, R., Engman, K. (1998) Survival in renal cell carcinoma – a randomized evaluation of tamoxifen vs interleukin 2, alfa-interferon (leucocyte) and tamoxifen. *Br. J. Cancer* **77**, 1311-1317.
- Huland, E., Heinzer, H., Mir, T. S., Huland, H. (1997) Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience. *Cancer J. Sci. Am.* **3**, S98-S105.
- Jeon, S. H., Chang, S. G., Kim, J. I. (1999) The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma. *Anticancer Res.* **19**, 5593-5597.
- Kirchner, H. H., Anton, P., Atzpodien, J. (1995) Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumour vaccines. *World J. Urol.* **13**, 171-173.
- Kirkpatrick, C. H. (2000) Transfer factors: identification of conserved sequences in transfer factor molecules. *Mol. Med.* **6**, 332-341.
- Kirsh, M. M., Orringer, M. B., McAuliffe, S., Schork, M. A., Katz, B., Silva, J. (1984) Transfer factor in the treatment of carcinoma of the lung. *Ann. Thorac. Surg.* **38**, 140-145.
- Kugler, A., Seseke, F., Thelen, P., Kallerhoff, M., Muller, G. A., Stuhler, G., Muller, C., Ringert, R. H. (1998) Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. *Br. J. Urol.* **82**, 487-493.
- Lasset, C., Merrouche, Y., Negrier, S., Rebattu, P., Berille, J., Bizzari, J. P., Chauvin, F., Philip, T. (1993) Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma. *Cancer Chem. Pharm.* **32**, 329-31.
- Lefevre, A., Viza, D., Patrasco, M., Phillips, J., De Vinci, C., Pizza, G. (1987) Interleukin-2 treatment of lung metastases of a mammary adenocarcinoma. *J. Exp. Pathol.* **3**, 533-537.
- Lissoni, P., Rovelli, F., Baiocco, N., Tangini, G., Fumagalli, L. (2001) A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. *Anticancer Res.* **21**, 777-779.
- Liu, J. H., Yang, M. H., Fan, F. S., Yen, C. C., Wang, W. S., Chang, Y. H., Chen, K. K., Chen, P. M. (2001) Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. *Urology* **57**, 650-654.
- Lopez-Hanninen, E., Poliwoda, H., Atzpodien, J. (1995) Interferon alpha/5 fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma. *Cancer Biother.* **10**, 21-24.
- Lopez-Hanninen, E. L., Kirkner, H., Atzpodien, J. (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. *J. Urol.* **155**, 19-25.
- Lummen, G., Sperling, H., Luboldt, H., Otto, T., Rubben, H. (1998) Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. *Cancer Chem. Pharm.* **42**, 415-417.
- McCune, C. S., O'Donnell, R. W., Marquis, D. M., Sahasrabudhe, D. M. (1990) Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumour cells. *Cancer Immunol. Immunother.* **32**, 62-66.
- Mertens, W. C., Eisenhauer, E. A., Jolivet, J., Ernst, S., Moore, M., Muldal, A. (1994) Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. *Ann. Oncol.* **5**, 185-187.
- Migliari, R., Muscas, G., Solinas, A., Melis, M., Ionta, M. T., Massidda, B., Usai, E. (1995) Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma? *J. Chemother.* **7**, 240-245.
- Miller, A. B., Hoogstraten, B., Staquet, M., Winkler, A. (1981) Reporting results of cancer treatment. *Cancer* **47**, 204-214.
- Miller, W. H., Reyno, L. M., Loewen, G. R., Huan, S., Winquist, E., Moore, M., Cato, A., Jaunakais, D., Truglia, J. A., Matthews, S., Dancey, J., Eisenhauer, E. A. (2000) A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study. *Ann. Oncol.* **11**, 1387-1389.
- Montie, J. E., Bukowski, R. M., Deodhar, S. H., Hewlett, J. S., Stewart, B. H., Straffon, R. A. (1977) Immunotherapy of disseminated renal cell carcinoma with transfer factor. *J. Urol.* **117**, 553-556.
- Montie, J. E., Bukowski, R. M., James, R. E., Straffon, J. A., Stewart, B. H. (1982) A critical review of immunotherapy of disseminated renal adenocarcinoma. *J. Surg. Oncol.* **21**, 5-8.
- Motzer, R. J., Murphy, B. A., Bacik, J., Schwartz, L. H., Nanus, D. M., Mariani, T., Loehrer, P., Wilding, G., Fairclough, D. L., Cella, D., Mazumdar, M. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. *J. Clin. Oncol.* **18**, 2972-2980.
- Naglieri, E., Gebbia, V., Durini, E., Lelli, G., Abbate, I., Selvaggi, F. P., Di Tonno, P., Colucci, G. (1998) Standard interleukin-2 (IL2) and interferon-alpha immunotherapy versus an IL2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma. *Anticancer Res.* **18**, 2021-2026.
- Negrier, S., Philip, T., Stoter, G., Fossa, S. D., Janssen, S., Iacone, A., Cleton, F. S., Eremin, O., Israel, L., Jasmin, C., Rugarli, C., Masse, H. V. D., Thatcher, N., Symann, M., Bartsch, H. H., Bergmann, L., Bijman, J. T., Palmer, P. A., Franks, C. R. (1989) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. *Eur. J. Cancer Clin. Oncol.* **25**, S21-S28.

- Negrier, S., Escudier, B., Lasset, C., Douillard, J. Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., Tursz, T. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. *N. Engl. J. Med.* **338**, 1272-1278.
- Negrier, S., Maral, J., Drevon, M., Vinke, J., Escudier, B., Philip, T. (2000) Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. *Cancer J. Sci. Am.* **6**, S93-S98.
- Neequaye, J., Viza, D., Pizza, G., Nkrumah, F. K., De Vinci, C., Levine, P. H. (1990) Transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma. *Anticancer Res.* **10**, 1183-1187.
- Nkrumah, F. K., Pizza, G., Neequaye, J., Viza, D., De Vinci, C., Levine, P. H. (1987) Transfer factor in prevention of Burkitt's lymphoma relapses. *J. Exp. Pathol.* **3**, 463-469.
- Olencki, T., Peereboom, D., Wood, L., Budd, G. T., Novick, A., Finke, J., McLain, D., Elson, P., Bukowski, R. M. (2001) Phase I and II trials of subcutaneously administered rIL2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma. *J. Cancer Res. Clin. Oncol.* **127**, 319-324.
- Oosterwijk, E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., Warnaar, S. O. (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. *Int. J. Cancer* **38**, 489-494.
- Paolorossi, F., Villa, S., Barni, S., Tancini, G., Andres, M., Lissoni, P. (1995) Second line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy. *Tumori* **81**, 45-47.
- Pilotti, V., Mastrorilli, M., Pizza, G., De Vinci, C., Busutti, L., Palareti, A. P., Gozzetti, G., Cavallari, A. (1996) Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. *Biotherapy* **9**, 117-121.
- Pizza, G., Viza, D., Fini, M., Cuzzocrea, D. E., Menniti, D., Corrado, F. (1980) Transitional cell carcinoma of the bladder. Differences between primary tumour and following relapses. *Eur. Urol.* **6**, 45-47.
- Pizza, G., Severini, G., Menniti, D., De Vinci, C., Corrado, F. (1984) Tumour regression after intralesional injection of interleukin-2 (IL2) in bladder cancer: preliminary report. *Int. J. Cancer* **34**, 359-367.
- Pizza, G., Severini, G., Menniti, D., De Vinci, C., Corrado, F. (1987) Interleukin 2 in the treatment of infiltrating bladder cancer. *J. Exp. Pathol.* **3**, 525-531.
- Pizza, G., Viza, D., De Vinci, C., Vich, I., Pascuchi, J. M., Busutti, L., Bergami, T. (1988) Intra-lymphatic administration of interleukin-2 (IL2) in cancer patients: a pilot study. *Lymphokine Res.* **7**, 45-48.
- Pizza, G., De Vinci, C., Cuzzocrea, D. E., Menniti, D., Aiello, E., Maver, P., Corrado, G., Romagnoli, P., Dragoni, E., Lo Conte, G., Riolo, U., Palareti, A. P., Zucchelli, P., Fornarola, V., Viza, D. (1996) A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. *Biotherapy* **9**, 133-138.
- Pizza, G., De Vinci, C., Aiello, A., Corrado, G., Lo Conte, G., Mazzuca, A., Baricordi, O. R., Vacca, A., Gulino, A., Fornarola, V., Capanna, R., Busutti, L. (1999) Gene-immunotherapy in metastatic renal-cancer (MRCC) using an allogeneic renal cancer cell-line engineered to produce interleukin-2 (IL2) and admixed with formalin-fixed autologous tumour cells: preliminary results in one patient. *Urologia* **66**, S18-S21.
- Pizza, G., De Vinci, C., Lo Conte, G., Paver, P., Dragoni, E., Aiello, E., Fornarola, V., Bergami, T., Busutti, L., Boriani, S., Palareti, A. P., Capanna, R. (2001) Immunotherapy of metastatic kidney cancer. *Int. J. Cancer* **94**, 109-120.
- Prasad, U., Jalaludin, M. A., Rajadurai, P., Pizza, G., De Vinci, C., Viza, D., Levine, P. H. (1997) Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: a pilot study. *Virus Res.* **47**, 134-135.
- Pyrhonen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., Juusela, H., Rintala, E., Hietanen, P., Kellokumpu-Lehtinen, P. L. (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. *J. Clin. Oncol.* **17**, 2859-2867.
- Reese, D. M., Corry, M., Small, E. J. (2000) Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma. *Cancer* **88**, 1310-1316.
- Repmann, R., Wagner, S., Richter, A. (1997) Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumour vaccine. *Anticancer Res.* **17**, 2879-2882.
- Rini, B. I., Vogelzang, N. J., Dumas, M. C., Wade, J. L., Taber, D. A., Stadler, W. M. (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. *J. Clin. Oncol.* **18**, 2419-2426.
- Ritchie, A. W. S., Griffiths, G., Parmar, M., Fossa, S. D., Selby, P. J., Cornbleet, M. A., Sibley, G., Mead, G. M., Kaye, S., Owen, J. R., Cook, P., Smith, P. H., Whelan, P., Fayers, P. M., Oliver, R. T. D., Whitehead, J. (1999) Interferon- α and survival in metastatic renal-cell carcinoma: early results of a randomized controlled trial. *Lancet* **353**, 14-17.
- Schendel, D. J., Frankenberger, B., Jantzer, P., Cayeux, S., Nobetaner, E., Willimsky, G., Maget, B., Pohla, H., Blankenstein, T. (2000) Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumour-associated cytotoxic T lymphocytes in the presence of an alloresponse. *Gene Therapy* **7**, 2007-2014.
- Schmidinger, M., Steger, G. G., Budinsky, A. C., Wenzel, C., Brodowicz, T., Locker, G. J., Kramer, G., Marberger, M., Zielinski, C. C. (2000a) Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinoma. *Anticancer Drugs* **11**, 175-179.
- Schmidinger, M., Steger, G. G., Wenzel, C., Locker, G. J., Brodowicz, T., Budinsky, A. C., Wiltshcke, C., Kramer, G., Marberger, M., Zielinski, C. C. (2000b) Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Austrian Renal Cell Carcinoma Study Group. *Cancer Immunol. Immunother.* **49**, 395-400.
- Schwaab, T., Heaney, J. A., Schned, A. R., Harris, R. D., Cole, B. F., Noelle, R. J., Phillips, D. M., Stempkowski, L., Ernstoff, M. S. (2000) A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. *J. Urol.* **163**, 1322-1327.
- Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. H., Finn, C. C., Clift, S. M., Beck, L. A., Leiferman, K. M., Owens, A. H. Jr., Piantadosi, S., Dranoff, G., Mulligan, R.

- C., Pardoll, D. M., Marshall, F. F. (1997) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. *Cancer Res.* **57**, 1537-1546.
- Steele, R. W., Myers, M. G., Vincent, M. M. (1980) Transfer factor for the prevention of varicella-zoster infection in childhood leukemia. *N. Engl. J. Med.* **303**, 355-359.
- Tsavaris, N., Baxevanis, C., Kosmidis, P., Papamichael, M. (1996) The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b. *Cancer Immunol. Immunother.* **43**, 94-102.
- Ueda, R., Ogata, S., Morrissey, D. M., Finstad, C. L., Szkudlarek, J., Whitmore, W. F., Oettgen, H. F., Lloyd, K. O., Old, L. J. (1981) Cell surface antigens: serological analysis of human renal cancer defined by mouse monoclonal antibodies: identification of tissue specific glycoproteins. *Proc. Natl. Acad. Sci. USA* **78**, 5122- 5126.
- Vaishampayan, U., Flaherty, L., Du, W., Hussain, M. (2001) Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. *Cancer* **92**, 519-523.
- van Herpen, C. M., Jansen, R. L., Kruit, W. H., Hoekman, K., Groenewegen, G., Osanto, S., De Mulder, P. (2000) Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. *Br. J. Cancer* **82**, 772-776.
- van Lommel, P., van Wees, R., Meyers, V., Elfferich, I. (2001) Near-death experience in survivors of cardiac arrest: a prospective study in the Netherlands. *Lancet* **358**, 2039-2045.
- Viza, D., Vich, J. M., Phillips, J., Rosenfeld, F., Davies, D. A. L. (1986) Specific transfer factor protects mice against lethal challenge with herpes simplex virus. *Cell Immunol.* **100**, 555-562.
- Wagner, G., Knapp, W., Gitsch, E., Selander, S. (1987) Transfer factor for adjuvant immunotherapy in cervical cancer. *Cancer Detect. Prev. (Suppl)* **1**, 373-376.
- Westermann, J., Reich, G., Kopp, J., Haus, U., Dorken, B., Pezzutto, A. (2001) Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. *Cancer Immunol. Immunother.* **49**, 613-620.
- Whyte, R. I., Schork, M. A., Sloan, H., Orringer, M. B., Kirsh, M. M. (1992) Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up. *Ann. Thorac.* **53**, 391-396.
- Yagoda, A., Abi-Rachmed, B., Petrylak, D. (1995) Chemotherapy for advanced renal cell carcinoma:1983-1993. *Semin. Oncol.* **22**, 42-60.